Ionis Pharmaceuticals specializes in developing and marketing RNA-targeted therapeutics, including antisense drugs. With a focus on disrupting disease processes and changing their course, Ionis has developed three approved medicines and has a strong pipeline of neurological and cardiometabolic treatments. The company's innovative drug discovery platform has led to breakthrough treatments for conditions such as spinal muscular atrophy and hereditary transthyretin amyloidosis. Ionis Pharmaceuticals is committed to providing hope and therapeutic options to patients with unmet medical needs.